Diego H. Caceres

Mr. Diego H. Caceres

Mycotic Diseases Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA, and Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FQFlavio Queiroz-Telles
Flavio Queiroz-Telles
Ahned FahalAhned Fahal
Ahned Fahal
DFDiego Rodrigues Falci
Diego Rodrigues Falci
DCDiego H. Caceres
Diego H. Caceres
TCTom Chiller
Tom Chiller
APAlessandro C Pasqualotto
Alessandro C Pasqualotto

26 October 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JRJohn Rossow
John Rossow
FQFlavio Queiroz-Telles
Flavio Queiroz-Telles
DCDiego H. Caceres
Diego H. Caceres
KBKarlyn Beer
Karlyn Beer
BJBrendan Jackson
Brendan Jackson
Sandro PereiraSandro Pereira
Sandro Pereira
Cat-transmitted sporotrichosis caused by Sporothrix brasiliensis has become a major public health concern and presents a distinct divergence from the traditional epidemiology of sporotrichosis. This emerging fungal pathogen spreads readily among cat populations, and human infections occur exclusively via zoonotic transmission. While sporotrichosis is an implantation mycosis that typically manifests as cutaneous lesions in humans and cats, severe extracutaneous manifestations are more common with S. brasiliensis than other Sporothrix species infections. Rapid diagnosis and appropriate treatment regimens are critical for successful clinical resolution of sporotrichosis in both cats and humans. Species-level identification of Sporothrix is possible with molecular diagnostics and necessary for tracking the geographic expansion of S. brasiliensis and better understanding its epidemiology. Combatting cat-transmitted sporotrichosis requires a One Health approach to successfully implement public health control measures.

28 November 2019 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DCDiego H. Caceres
Diego H. Caceres
KFKaitlin Forsberg
Kaitlin Forsberg
RWRory Welsh
Rory Welsh
DSDavid Joseph Sexton
David Joseph Sexton
Shawn R LockhartShawn R Lockhart
Shawn R Lockhart
TCTom M. Chiller
Tom M. Chiller
Candida auris is an emerging multidrug-resistant fungal pathogen. Since first reported in 2009, C. auris has caused healthcare outbreaks around the world, often involving high mortality. Identification of C. auris has been a major challenge as many common conventional laboratory methods cannot accurately detect it. Early detection and implementation of infection control practices can prevent its spread. The aim of this review is to describe recommendations for the detection and control of C. auris in healthcare settings.

1 July 2019 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PAPaige A Armstrong
Paige A Armstrong
SRSandra M Rivera
Sandra M Rivera
PEPatricia Escandon
Patricia Escandon
DCDiego H. Caceres
Diego H. Caceres
NCNancy Chow
Nancy Chow
OPOscar Pacheco
Oscar Pacheco
Adherence to infection control recommendations is critical to prevent spread of this novel yeast.

25 September 2017 in Mycoses
Verified
Journal Article
Open access
PDF file
AAana Belen Arauz
ana Belen Arauz
DCDiego H. Caceres
Diego H. Caceres
ESErika Santiago
Erika Santiago
PAPaige Armstrong
Paige Armstrong
SASusan Arosemena
Susan Arosemena
TCTom Chiller
Tom Chiller
Summary: Candida auris is an emerging multidrug‐resistant (MDR) fungus associated with invasive infections and high mortality. This report describes 9 patients from whom C. auris was isolated at a hospital in Panama City, Panama, the first such cases in Central America, and highlights the challenges of accurate identification and methods for susceptibility testing.

18 August 2019 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DCDiego H. Caceres
Diego H. Caceres
MKMartha Knuth
Martha Knuth
GDGordana Derado
Gordana Derado
MLMark D. Lindsley
Mark D. Lindsley
Histoplasmosis is an important cause of mortality in people with advanced HIV, especially in countries with limited access to diagnostic assays. Histoplasmosis can be diagnosed using culture, histopathology, and antibody, antigen, and molecular assays. Several factors may affect the analytical performance of these laboratory assays, including sample type, clinical stage of the disease, and previous use of antifungal treatment, among others. Here we describe the results of a systematic literature review, followed by a meta-analysis of the analytical performances of the diagnostic laboratory assays employed. Our initial search identified 1631 references, of which 1559 references were excluded after title and abstract screening, leaving 72 references identified as studies relevant to the validation of histoplasmosis diagnostic assays. After evaluating the full text, 30 studies were selected for final review, including one paper not identified in the initial search. The meta-analysis for assay analytical performance shows the following results for the overall sensitivity (Sen) and specificity (Spe) of the various methods evaluated: Culture, Sen 77% (no data for specificity calculation); antibody detection assays, Sen 58%/Spe 100%; antigen detection assays, Sen 95%/Spe 97%; and DNA detection assays (molecular), Sen 95%/Spe 99%. Of the 30 studies reviewed, nearly half (n = 13) evaluated Histoplasma antigen assays, which were determined to be the most accurate methodology for diagnosis of progressive disseminated histoplasmosis in advanced HIV (inverse of the negative likelihood ratio was 13.2). Molecular assays appear promising for accurate diagnosis of histoplasmosis, but consensus on exact techniques is needed. Cultures showed variable sensitivity related to sample type and laboratory handling. Finally, antibody assays presented high specificity but low sensitivity. This poor sensitivity is most likely due the highly immunosuppressed state of this patient population. Diagnostic assays are crucial for accurate diagnosis of progressive disseminated histoplasmosis (PDH) with advanced HIV disease.